How MedTech Investors Test Product-Market Fit

When an investor asks about product-market fit in MedTech, they are not asking whether doctors like the product or whether it worked in a pilot. They are asking whether the early commercial signals are specific enough to underwrite the next stage of capital, and whether they believe you can achieve the next set of critical milestones with the runway that capital provides.

What Investors are Really Looking For

In most B2B categories, revenue is treated as the clearest measure of product-market fit. Once customers are paying at a rate that supports the model, the fit is largely taken as given. MedTech does not work that way. Revenue is a lagging indicator. Multi-stakeholder buying, long sales cycles, reimbursement uncertainty, and the distance between clinical validation and budget authority all mean a company can show real clinical interest long before meaningful revenue appears. Investors know this, so they look for earlier, more specific signals of commercial progress.

Stifel Venture Banking noted in mid-October 2026 that commercial readiness is now part of the financing story by Series A and often earlier. Investors want a clearer view of the buyer, the reimbursement pathway, clinical workflow, and the path to meaningful revenue alongside the clinical and regulatory story.

Vikram Chaudhery, Partner at Genoa Ventures, described it this way: “The focus of an underwrite used to be technical and scientific feasibility and the regulatory roadmap. You still asked about reimbursement and go-to-market, but a rudimentary answer was good enough.” He added that questions about buyer and economics can have great answers in a conference room, but “the field is the only real litmus test. When spend is theoretical, everyone is a billionaire. When you have to part with dollars, stakeholder alignment becomes the driving force and intentions reveal themselves.”

Martyn Eeles made a similar point in his May 7, 2026 HealthVC note: “Clinical value is not commercial value.” Investors are increasingly asking whether the company understands the system around the product, not only whether the product works.

7 Red Flags

In Seed and even Series A rounds, the real test is whether you can speak to a core set of risks with enough specificity to convince an investor that the market risks are surmountable and you know how to execute. Specifically:

1. Economic buyer clarity. Who has budget authority, and has that person already engaged in a conversation that involves real spend or a path to it? A clinical champion who likes the product is useful, but investors treat it as incomplete until the economic conversation has started.
   
   
2. Paid pilots or specific LOIs. Specialist investors have grown skeptical of vanity LOIs that list a hospital or system without naming volume, price, or what converts the interest into revenue. They often call the signatory. A paid pilot under a narrow, compliant scope is stronger still because it shows willingness to pay while generating evidence.
   
   
3. Reimbursement Clarity. Concrete progress in at least one market, whether that is an engaged payer conversation, a coding strategy with dates, or a clear view of the pathway and the capital required to advance it. Investors do not expect the pathway to be finished. They expect the founder to know which questions matter and what it will cost to answer them.
   
   
4. Feasible economic model. Early willingness-to-pay signals, budget-impact thinking, or directional feedback from purchasing or value analysis teams. When real dollars enter the conversation, misaligned incentives become visible, and investors want to see that the founder has already encountered and understood them.
   
   
5. Conversion or expansion signals. Evidence that a first site is moving from trial to ongoing use, or that a second site is looking more like a repeat than a custom project. A pipeline full of pilots can look active. Investors want to see whether any of them are turning into paid, expanded, or embedded relationships, or at least a documented path for how that happens.
   
   
6. Realistic timeline assumptions. These show up in the model and in diligence questions about how long it takes to get from first conversation to decision, how much physician or operational education is required, and whether the product fits existing workflows or adds net burden. Conference-room answers are discounted. Field-tested ones are not.
   
   
7. Initial market clarity. Investors notice when a company presents too many markets, use cases, or buyer types at once. They are asking where the company should start, why that starting point is the strongest one, and what it proves about the larger opportunity. Breadth without a clear first investment case reads as unfinished thinking.

Don't think about this as an ironclad checklist you have to meet before you can raise. Think about it as a test of conviction - can you speak to each with enough clarity and specificity that investors will believe you understand and know how to approach and mitigate each risk. Which risks are known, which are still open, and whether the next round of capital will fund progress against the open ones.

Reference calls and data-room review often test the same points. Investors speak with customers, advisors, and other market participants to see whether the founder’s description of traction matches what the market will confirm. Gaps between the two can stop an investor conversation cold.

How to pressure-test it yourself

Replay the last two or three commercial conversations you've had. For each one, ask yourself (1) do I understand the buyer map; (2) is the reimbursement or business model clear; and (3) can I map out specific next steps that will lead to a successful close?

Look at whether any site is showing expansion signals and whether your assumptions on sales cycle length and implementation schedules actually match what you're seeing in the field. If you can't answer, or if the answers are weak, you won't survive the diligence process. Instead, take a step back, clearly identify the gaps in the answers and do the work to fill them before you ask investors to trust you with their money.

The 7-Lever Self-Assessment is built for companies at this stage: early validation signals that still need to be converted into commercial foundations investors will fund. It walks through the buyer, economic, workflow, and evidence questions that decide whether early interest becomes a motion that supports the next round. If the results point to specific gaps you want to work through, book a strategy call, and we can talk about how to help you close those gaps.